We are excited to introduce a new offering to our product portfolio: Neuron-D’s 3D platform – a 3D cell culture drug testing platform for glioblastoma multiforme (GBM). GBM is the most common malignant brain tumor among adult patients and almost universally fatal.
Despite the recent leaps in knowledge about the genome, epigenome, and transcriptome of GBM, clinical outcomes in GBM have not changed over the years. Therapies that perform well in preclinical studies frequently fail expensive Phase III clinical trials. Therefore, there is a great need for an efficient and effective technology that enables the identification and vetting of potential drugs at the preclinical stage that will demonstrate efficacy at late-stage clinical trials. We urgently need novel compounds, or combinations of compounds that prevent the disease from spreading and improve survival.
Our 3D platform is the world’s 1st patented and award-winning 3D starPEG-Heparin hydrogel technology adapted platform. It enables drug developers to test the efficacy, safety and pharmacokinetics of candidate compounds for GBM in a three-dimensional, physiologically relevant tumor environment. The platform mimics tumor composition and physiology far more precisely than the state-of-the-art 2D cell culture methods. Our technology will yield in more reliable readouts for therapeutic efficacy and thereby provide a higher predictive outcome for further in vivo testing.
We provide a technology that will generate more viable drug candidates early on in the drug development pathway. This will allow developers to identify candidates with a greater probability of success in clinical trial early on, thereby reducing costs and time of development. We help you pick the right compound earlier, faster and cheaper!
We welcome the opportunity to talk to you about your needs in selecting the best drug candidates and how we can fill in the gaps. We are here to empower you by strengthening your drug portfolio in order to bring the most effective solutions to patients.